Fulgent Genetics Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $873.17 million
- Book Value:
- Revenue TTM:
- $618.97 million
- Operating Margin TTM:
- Gross Profit TTM:
- $366.90 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Fulgent Genetics Inc had its IPO on 2016-09-29 under the ticker symbol FLGT.
The company operates in the Healthcare sector and Diagnostics & Research industry. Fulgent Genetics Inc has a staff strength of 1,012 employees.
Shares of Fulgent Genetics Inc opened at $30.01 at the start of the last trading session i.e. 2023-03-30.
The stocks traded within a range of $29.24 - $30.3, and closed at $29.69.
This is a -0.37% slip from the previous day's closing price.
A total volume of 172,387 shares were traded at the close of the day’s session.
In the last one week, shares of Fulgent Genetics Inc have slipped by -1.98%.
Fulgent Genetics Inc's Key Ratios
Fulgent Genetics Inc has a market cap of $873.17 million, indicating a price to book ratio of 0.7978 and a price to sales ratio of 1.1613.
In the last 12-months Fulgent Genetics Inc’s revenue was $618.97 million with a gross profit of $366.90 million and an EBITDA of $222.94 million. The EBITDA ratio measures Fulgent Genetics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Fulgent Genetics Inc’s operating margin was 30.83% while its return on assets stood at 8.95% with a return of equity of 11.65%.
In Q4, Fulgent Genetics Inc’s quarterly earnings growth was a negative -98.6% while revenue growth was a negative 73.1%.
Fulgent Genetics Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $4.59 per share while it has a forward price to earnings multiple of 7.9365 and a PEG multiple of 1.32. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fulgent Genetics Inc’s profitability.
Fulgent Genetics Inc stock is trading at a EV to sales ratio of 0.5832 and a EV to EBITDA ratio of 1.1847. Its price to sales ratio in the trailing 12-months stood at 1.1613.
Fulgent Genetics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.39 billion
- Total Liabilities
- $88.11 million
- Operating Cash Flow
- Capital Expenditure
- $5.28 million
- Dividend Payout Ratio
Fulgent Genetics Inc ended 2023 with $1.39 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.39 billion while shareholder equity stood at $1.27 billion.
Fulgent Genetics Inc ended 2023 with $0 in deferred long-term liabilities, $88.11 million in other current liabilities, 3000.00 in common stock, $801.00 million in retained earnings and $143.03 million in goodwill. Its cash balance stood at $79.51 million and cash and short-term investments were $526.24 million. The company’s total short-term debt was $20,638,000 while long-term debt stood at $0.
Fulgent Genetics Inc’s total current assets stands at $627.87 million while long-term investments were $339.03 million and short-term investments were $446.73 million. Its net receivables were $75.11 million compared to accounts payable of $23.09 million and inventory worth $4.28 million.
In 2023, Fulgent Genetics Inc's operating cash flow was $0 while its capital expenditure stood at $5.28 million.
Comparatively, Fulgent Genetics Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Fulgent Genetics Inc stock is currently trading at $29.69 per share. It touched a 52-week high of $65.17 and a 52-week low of $65.17. Analysts tracking the stock have a 12-month average target price of $41.67.
Its 50-day moving average was $32.43 and 200-day moving average was $40.28 The short ratio stood at 4.84 indicating a short percent outstanding of 0%.
Around 3378.9% of the company’s stock are held by insiders while 4559.7% are held by institutions.
Frequently Asked Questions About Fulgent Genetics Inc
Similar Industry Stocks (Diagnostics & Research)
Fulgent Genetics, Inc., together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and next generation sequencer services related to hereditary cancer, cardiovascular genetics, reproductive health, and neurodegenerative genetics, as well as pharmacogenetic tests. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to enhance the therapeutic window and pharmacokinetic profile, or PK profile, of new and existing cancer drugs. The company also operates picture genetics platform which includes proprietary gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.